바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


진료과

  • 연세암병원-종양내과

전문진료분야

  • [강의분야] 병리학, 종양학, 유전체학 [연구관심분야] ○ 종양학 (유방암 및 대장암) ○ 인간 유전체 분석 및 중개연구 ○ 개인 맞춤 항암치료 ○ 임상 유전체 분석 및 질병 원인 변이 발견

진료시간표

전화예약만 가능1599-1004
의사시간표
진료시간
오전 암병원 암병원 암병원 암병원 암병원
오후

교육 및 임상 경력

  • 1983-1985:  Shadyside  Hospital  /  Resident
  • 1985-1986:  State  University  of  New  York  Health  Science  Center  at  Brooklyn/  Resident
  • 1986-1987:  State  University  of  New  York  Health  Science  Center  at  Brooklyn/ 
  •                         Subspecialty  Resident  in  Neuropathology
  • 1987-1988:  Medicine  Branch,  National  Cancer  Institute/  Senior  Staff  Fellow
  • 1988-1990:  Lombardi  Cancer  Center,  Georgetown  University/  Post-docoral  fellow
  • 1990-1995:  Lombardi  Cancer  Center,  Georgetown  Universtiy/  Assistant  Professor
  • 1995-1999:  Pathology  Section,  NSABP/  Co-Director
  • 1999.6.1.~present:  Division  of  Pathology,  NSABP  Foundation/  Director
  • 2009-2012:  Samsung  Cancer  Research  Institute,  Samsung  Medical  Center/  Director

학술관련경력

  • 2010 Susan Komen Foundation Brinker Award for Scientific Distinction for Breast Cancer Research
  • 2011 Distinguished Alumni Award, Yonsei University
  • 2010~ Member, NCI Breast Cancer Steering Committee
  • 2000~ Member, Program for the Assessment of Clinical Cancer Tests (PACCT), NCI
  • 2006~ Member, Early Breast Cancer Trialists Group (EBCTCG) Steering Committee

주요 관심분야

  • Development of prognostic and predictive tests for breast and colorectal cancer
  • Clinical trial design

학력사항

  • 1975-1977: 연세대학교 의예과
  • 1977-1981: 연세대학교 의과대학 의사 의학

논문

  • 1: Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D,Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, RomondEH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S. Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP TrialB-31. J Natl Cancer Inst. 2013 Nov 21. [Epub ahead of print] PubMed PMID:24262440.
  • 2: Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, BlackmonN, Lipchik C, Kim SR, Sharif S, Allegra C, Petrelli N, O'Connell MJ, Wolmark N,Paik S. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst. 2013 Jul 3;105(13):989-92. PubMed PMID: 23821759
  • 3: Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in thetreatment and prevention of estrogen receptor-positive breast cancer. J ClinOncol. 2011 Nov 1;29(31):4160-7. PubMed PMID: 21947828
  • 4: Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation ofprognostic and predictive biomarkers. J Natl Cancer Inst. 2009 Nov4;101(21):1446-52. PubMed PMID:19815849.
  • 5: Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab inbreast cancer. N Engl J Med. 2008 Mar 27;358(13):1409-11. PubMed PMID: 18367751.
  • 6: Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D,Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene expressionand benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006 Aug 10;24(23):3726-34. PubMed PMID: 16720680.
  • 7: Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec 30;351(27):2817-26. PubMed PMID:15591335.
  • Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 105/Issue :1782-1788,2013
  • Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 105/13 :989-992,2013
  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
    LANCET 384/9938 :164-172,2014
  • Nanomaterials for theranostics: Recent advances and future challenges
    CHEMICAL REVIEWS 115/1 :327-394,2015
  • Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
    CLINICAL CANCER RESEARCH 21/3 :544-552,2015
  • Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
    YONSEI MEDICAL JOURNAL 56/5 :1186-1198,2015
  • Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
    JOURNAL OF CLINICAL ONCOLOGY 33/12 :1340-1347,2015
  • A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2
    BREAST CANCER RESEARCH AND TREATMENT 149/2 :517-523,2015
  • Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): Secondary outcomes of a phase 3, randomised controlled trial
    LANCET ONCOLOGY 16/9 :1037-1048,2015
  • Prognostic tests for estrogen receptor-positive breast cancer: Need for global consideration and further evolution
    JAMA oncology 3/- :E1-E3,2015
  • Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
    MOLECULAR CANCER THERAPEUTICS 14/10 :2238-2248,2015
  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
    NEW ENGLAND JOURNAL OF MEDICINE 373/21 :2005-2014,2015
  • Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
    ONCOTARGET 6/42 :44971-44984,2015
  • CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
    NEW ENGLAND JOURNAL OF MEDICINE 374/3 :211-222,2016
  • Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.
    Oncogenesis 5/7 :e241-,2016
  • Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
    ONCOTARGET 7/17 :24,172-24,178,2016
  • EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines
    MOLECULAR CANCER THERAPEUTICS 15/7 :1,627-1,636,2016
  • Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes Secondary Analysis of NSABP C-O7/NRG Oncology Randomized Clinical Trial
    JAMA Oncology 2/9 :1162-1169,2016
  • Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer
    BREAST CANCER RESEARCH AND TREATMENT 163/2 :255-262,2017
  • Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
    ONCOTARGET 8/24 :39,367-39,381,2017
  • Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
    ANNALS OF ONCOLOGY 28/6 :1,250-1,259,2017
  • Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
    ONCOTARGET 8/24 :38,389-38,398,2017
  • 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 109/4 :1-8,2017
  • The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
    ANNALS OF SURGICAL ONCOLOGY 24/7 :1,853-1,860,2017
  • Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in
    ADVANCES IN ANATOMIC PATHOLOGY 24/5 :235-251,2017
  • Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial
    JAMA oncology 3/3 :335-341,2017
  • AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing
    BIOINFORMATICS 34/7 :1,232-1,234,2018
  • Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information
    ANNALS OF ONCOLOGY 29/4 :1,030-1,036,2018
  • Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells with Markers of the Epithelial?Mesenchymal Transition, Due to Loss of NAPRT
    GASTROENTEROLOGY 155/3 :799-814,2018
  • Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth
    GENOME RESEARCH 28/3 :374-382,2018
  • Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    LUNG CANCER 124/ :168-178,2018
  • Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
    BRITISH JOURNAL OF CANCER 118/5 :629-633,2018
  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
    NEW ENGLAND JOURNAL OF MEDICINE 379/2 :111-121,2018
  • 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology
    BREAST CANCER RESEARCH AND TREATMENT 168/1 :69-77,2018
  • Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab
    PHARMACOGENETICS AND GENOMICS 28/6 :147-152,2018
  • Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations
    PLOS ONE 13/8 :e0200836-,2018
  • Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer
    BRITISH JOURNAL OF CANCER 119/11 :1,347-1,357,2018
  • Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial
    LANCET ONCOLOGY 20/1 :88-99,2019
  • A therapeutic strategy for chemotherapy-resistant gastric cancer via destabilization of both β-catenin and ras
    Cancers 11/4 :496-1-496-16,2019
  • Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
    NEW ENGLAND JOURNAL OF MEDICINE 380/25 :2,395-2,405,2019
  • Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 111/8 :867-871,2019

백순명

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보